OKYO Pharma Announces Successful Type C Meeting with the FDA

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...

Pro-life organization calls on HHS and FDA to suspend abortion pill approval, tighten safety rules

Live Action alleges "reckless distribution" of the abortion drug mifepristone, urging the Trump administration to suspend its ...

Some drugmakers quietly concerned about legal risk with speedy FDA review program

By Maggie Fick and Patrick Wingrove SAN FRANCISCO, Jan 16 (Reuters) - More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new medicines, ...
The National Law Review

uniQure Announces Type A Meeting Scheduled with FDA

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

Takeaways from the AP's report on turmoil surrounding the FDA's new fast-track drug program

A plan to slash drug review times at the Food and Drug Administration is sparking deep concerns among agency staffers and outside experts, with some saying the poorly defined effort is taking key ...
MarketWatch

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...

Legal questions swirl around FDA's new expedited drug program, including who should sign off

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...
JD Supra

Investors Prepare to Navigate FDA Crosswinds Ahead of the J.P. Morgan Healthcare Conference

Troutman Pepper Locke partners Chris Miller and Judy O'Grady sit down to discuss recent policy shifts at the FDA and what they mean for life sciences investors attending the 44th Annual J.P. Morgan ...